Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/dth.14746 http://scihub22266oqcxt.onion/10.1111/dth.14746 33405372!7883269!33405372     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Dermatol+Ther 2021 ; 34 (2): e14746 Nephropedia Template TP {{tp|p=33405372|t=2021. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic |pdf=|usr=}}{{33405372}} gab.com Text Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic JO: Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33405372 #FOAvip Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P < .001). Statistically significant relationships of age (P = .013) and treatment duration (P < .001) to recurrence were also found. The change in the SALT score differed between the patients on therapy and off therapy during the pandemic (P < .001). A significant negative correlation was found between the change in the SALT score and treatment duration: the spearman correlation test P = .018. We concluded that the patients may continue to the tofacitinib therapy during the rest of the COVID-19 pandemic if the benefit outweighed the risk. Twit Text FOAVip Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic ????Dermatol Ther http://www.kidney.de/pget.php?&tw=1&pmid=33405372 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33405372 #FOAvip English Wikipedia <ref>{{Cite pmid|33405372}}</ref> Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic #MMPMID33405372 Askin O; Ozkoca D; Uzuncakmak TK; Serdaroglu S Dermatol Ther 2021[Mar]; 34 (2): e14746 PMID33405372show ga Tofacitinib is a Janus Kinase 3 inhibitor that is used in the treatment of alopecia areata. We recommended our alopecia areata patients to discontinue their tofacitinib treatment during the COVID-19 pandemic for an average of 80 days. We aimed to evaluate the drug use and the SARS-CoV-2 infection status of alopecia areata patients; and the relationships of recurrence to age, gender, treatment duration, and tofacitinib discontinuation. One-hundred and ninety-one (61.4%) patients were off the drug and 120 (38.6%) were on therapy during the pandemic. The relationship between drug discontinuation due to the COVID-19 pandemic and recurrence was statistically significant (P < .001). Statistically significant relationships of age (P = .013) and treatment duration (P < .001) to recurrence were also found. The change in the SALT score differed between the patients on therapy and off therapy during the pandemic (P < .001). A significant negative correlation was found between the change in the SALT score and treatment duration: the spearman correlation test P = .018. We concluded that the patients may continue to the tofacitinib therapy during the rest of the COVID-19 pandemic if the benefit outweighed the risk. |*Alopecia Areata/diagnosis/drug therapy/epidemiology[MESH] |*COVID-19[MESH] |Humans[MESH] |Pandemics[MESH] |Piperidines[MESH] |Pyrimidines[MESH]Evaluation of the alopecia areata patients on tofacitinib treatment du(epmc).pdf DeepDyve Pubget Overpricing